1 / 26

Optimal Medication Uptitration in Heart Failure: Achieving and Maintaining Target Doses

Explore the efficacy of uptitration of medications in heart failure management, focusing on achieving and sustaining target doses for improved outcomes. Learn about key guidelines, variations in titration steps, benefits, challenges, and solutions for optimal dosing.

suchin
Download Presentation

Optimal Medication Uptitration in Heart Failure: Achieving and Maintaining Target Doses

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Uptitration of Medications in HF: Start Low but Aim High and Stay High

  2. Treatment of HFrEF: What Have We Achieved?

  3. 2016 ESC HF Guidelines for Chronic HF Management

  4. ESC 2016 Guidelines for HF: Evidence-Based Disease Modifying Therapies With Recommended Doses

  5. Diuretic Use in HFrEF

  6. Variation in Drug Titration Steps to Achieve Optimal Dosing

  7. HEAAL: Benefit of Achieving Target Dose With ARB Therapy

  8. Target Doses in HFrEF Yield Better Outcomes

  9. BIOSTAT-CHF: How Are We Doing With Uptitration?

  10. ESC HF Long-Term RegistryUse of Pharmacological Therapies

  11. ESC HF Long-Term RegistryPatients at Target Dose With Recommended Drug Therapies

  12. HFrEF With AF: Decreased Benefit With BB

  13. CIBIS-ELD: Beta Blockade Use in the Elderly With HF

  14. TITRATION Study: Uptitration of Sacubitril/Valsartan

  15. Gaps Between What Is Achievable in Clinical Trials and the "Real World"

  16. Germany "Real World Data": Sacubitril/Valsartan Use Results

  17. Underdosing of NOACs in Anticoagulation for NVAF

  18. Why Are Drugs Not Uptitrated in HFrEF?

  19. Legitimate Reasons for Not Uptitrating Drug Doses

  20. Managing Renal Impairment and Hyperkalemia With Uptitration of RAS Inhibitors

  21. Less Legitimate Reasons for Not Uptitrating Drug Doses in HFrEF

  22. BIOSTAT CHF: Reasons for Not Uptitrating Therapies

  23. Solutions for Improving Drug Uptitrations

  24. Conclusions

  25. Abbreviations

  26. Abbreviations (cont)

More Related